Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: Effective treatment with eculizumab followed by rituximab

Transfusion

Volumn 55, Issue 10, 2015, Pages 2398-2403

  Boonyasampant, Mark ^a   Weitz, Ilene C ^b   Kay, Brian ^a   Boonchalermvichian, Chaiyaporn ^b   Liebman, Howard A ^b   Shulman, Ira A ^a  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BILIRUBIN; CIPROFLOXACIN; COLD AGGLUTININ; COMPLEMENT COMPONENT C5; CREATININE; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; IH ANTIBODY; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; RITUXIMAB; UNCLASSIFIED DRUG; ALLOANTIBODY; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBODY TITER; ARTICLE; BLOOD TRANSFUSION REACTION; CASE REPORT; CHRONOTHERAPY; COMPASSIONATE USE; COOMBS TEST; CREATININE BLOOD LEVEL; DELAYED HYPERHEMOLYTIC TRANSFUSION REACTION; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR HEMOLYSIS; MAINTENANCE THERAPY; MENINGOCOCCEMIA; MENINGOCOCCOSIS; RARE DISEASE; ROOM TEMPERATURE; SICKLE CELL ANEMIA; TREATMENT DURATION; TREATMENT RESPONSE; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; BLOOD; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; DRUG EFFECTS; HEMOLYSIS;

ADULT; ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; FEMALE; HEMOLYSIS; HUMANS; ISOANTIBODIES; RITUXIMAB;

EID: 84943816830     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13144     Document Type: Article

References (27)

1. Garratty G,. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 1997; 37: 357-61.
2. King KE, Shirey RS, Lankiewicz MW, et al., Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 1997; 37: 376-81.
3. Petz LD, Calhoun L, Shulman IA, et al., The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997; 37: 382-92.
4. Scheunemann LP, Ataga KI,. Delayed hemolytic transfusion reaction in sickle cell disease. Am J Med Sci 2010; 339: 266-9.
5. Win N, New H, Lee E, et al., Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008; 48: 1231-38.
6. Chadebech P, Nzouakou R, Bachir D, et al., Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009; 49: 1785-92.
7. Test ST, Woolworth VS,. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of the membrane attack complex formation. Blood 1994; 83: 842-52.
8. Roback J, Grossman B, Harris T, et al., Technical manual. 17th ed. Bethesda: American Association of Blood Banks; 2011.
9. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F,. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120: 528-37.
10. Darabi K, Makar S,. Acute hemolysis of transfused A2 red cells by an auto-HI antibody. Transfusion 2008; 48: 964-8.
11. Read SM, Whiteoak EJ, Benjamin RJ,. Unusual IH-like antibody implicated in delayed hemolytic transfusion reaction [abstract]. Transfusion 2003; 43 (Suppl): 101A.
12. Campbell SA, Shirey RS, King KE, et al., An acute hemolytic transfusion reaction due to anti-IH in a patient with sickle cell disease. Transfusion 2000; 40: 828-31.
13. Arndt P, Garratty G, Haverty D, et al., Clinically significant anti-HI in two patients with greatly increased i antigen on their red cells [abstract]. Blood 1997; 90 (Suppl 1): 472a.
14. Takeda J, Miyata T, Kawagoe K, et al., Deficiency of GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703-11.
15. Frimat M, Tabarin F, Dimitrov J, et al., Complement activation by heme as a second hit for atypical hemolytic uremic syndrome. Blood 2013; 122: 282-92.
16. Ihanus E, Uotila LM, Toivanen A, et al., Red-cell ICAM-4 is ligand for monocyte/macrophage integrin CD11c/C18: characterization of the binding site on ICAM-4. Blood 2007; 109: 802-10.
17. Aragona E, Kelly MT,. Hyperhemolysis in sickle cell disease. J Pediatr Hematol Oncol 2014; 36: e54-6.
18. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al., Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006; 47: 253-60.
19. Berentsen S,. How I manage cold agglutinin disease. Br J Haematol 2011; 153: 309-17.
20. Noizat-Pirenne F, Bachir D, Chadebech P, et al., Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007; 92: e132-5.
21. Bachmeyer C, Maury J, Parrot A, et al., Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010; 85: 91-2.
22. Taylor RP, Lindorfer LA,. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3: 86-95.
23. Hillmen P, Young NS, Schubert J, et al., The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-43.
24. Legendre CM, Licht C, Muus P, et al., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2012; 368: 2169-81.
25. Röth A, Hüttmann A, Rother RP, et al., Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009; 113: 3885-86.
26. Weinstock C, Möhle R, Dorn C, et al., Successful use of eculizumab for treatment of an acute hemolytic transfusion reaction after ABO-incompatible red blood cell transfusion. Transfusion 2015; 55: 605-10.
27. Gupta S, Fenves A, Nance ST, et al., Hyperhemolysis in a patient without hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion 2015; 55: 623-8.